Literature DB >> 22802129

Historical aspects of Pott's disease (spinal tuberculosis) management.

Surendar M Tuli1.   

Abstract

INTRODUCTION: Spinal tuberculosis has existed in human beings since the ascent of man on earth. Historically, the management has progressed from regional orthodox therapies to the current, more effective, drugs.
MATERIALS AND METHODS: Historical perspectives regarding the management have been collated by going through the important publications during the past 6 decades. For convenience, the manuscript has been organized as "orthodox traditional" treatment, early "chemotherapy period", "post chemotherapy treatment", "middle-path" philosophy, and the current treatment with availability of modern imaging facilities.
CONCLUSIONS: Broad conclusions based upon the published data and personal observations (1959-2011) are summarized as follows: If diagnosis is made at predestructive stage and the patient is treated by standard drugs, the infection would heal in about 95 % patients without significant deformities and complications. Neural complications are still encountered in general hospital outpatients. Diagnosis and treatment at early stages would resolve the neurology without operation in about 40 % of cases. Nearly 60 % of patients would require to be operatively decompressed without jeopardizing mechanical stability. However, despite current treatment approximately 8 % of tuberculous paraplegics do not recover functionally. Immunocompromised state and multidrug resistance to standard drugs (8 to 10 %) are the current (and future) challenges to the doctors and the society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22802129      PMCID: PMC3691412          DOI: 10.1007/s00586-012-2388-7

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  49 in total

1.  TREATMENT FOR TUBERCULOSIS OF THE SPINE. ANTI-TUBERCULOSIS DRUGS IN CONJUNCTION WITH RADICAL OPERATION AND SHORT HOSPITALIZATION WITH NO ENFORCED RECUMBENCY OR IMMOBILIZATION.

Authors:  B PAUS
Journal:  Acta Orthop Scand Suppl       Date:  1964

2.  Anterior spinal fusion. The operative approach and pathological findings in 412 patients with Pott's disease of the spine.

Authors:  A R HODGSON; F E STOCK; H S FANG; G B ONG
Journal:  Br J Surg       Date:  1960-09       Impact factor: 6.939

3.  Distribution and excretion of radioactive isoniazid in tuberculous patients.

Authors:  W R BARCLAY; R H EBERT; G V LE ROY; R W MANTHEI; L J ROTH
Journal:  J Am Med Assoc       Date:  1953-04-18

4.  Anterior instrumentation for the treatment of spinal tuberculosis.

Authors:  C Yilmaz; H Y Selek; I Gürkan; B Erdemli; Z Korkusuz
Journal:  J Bone Joint Surg Am       Date:  1999-09       Impact factor: 5.284

5.  Early results of treatment of spinal tuberculosis by triple drug therapy.

Authors:  S M Tull; S Kumar
Journal:  Clin Orthop Relat Res       Date:  1971 Nov-Dec       Impact factor: 4.176

6.  Tuberculosis of the spine treated by chemotherapy and operative débridement. A long-term follow-up study.

Authors:  M C Wilkinson
Journal:  J Bone Joint Surg Am       Date:  1969-10       Impact factor: 5.284

7.  Pott's paraplegia.

Authors: 
Journal:  Br Med J       Date:  1968-06-15

8.  Don't forget tuberculosis.

Authors:  S Patel; D A Collins; B E Bourke
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

9.  Pott's paraplegia treated by antero-lateral decompression in the thoracic and lumbar spine. A report of twenty-seven cases.

Authors:  A Langenskiöld; E B Riska
Journal:  Acta Orthop Scand       Date:  1967

Review 10.  Tuberculosis of the spine: a review.

Authors:  Anil K Jain; Ish Kumar Dhammi
Journal:  Clin Orthop Relat Res       Date:  2007-07       Impact factor: 4.176

View more
  27 in total

1.  Single-stage anterior debridement, posterior instrumentation and global fusion in thoracic and thoracolumbar tubercular spondylodiscitis.

Authors:  S P Mohanty; M Pai Kanhangad; B Yogesh Kumar; A Singh
Journal:  Musculoskelet Surg       Date:  2018-12-04

2.  History of spine surgery for tuberculous spondylodiscitis.

Authors:  S Rajasekaran; R M Kanna; A P Shetty
Journal:  Unfallchirurg       Date:  2015-12       Impact factor: 1.000

Review 3.  Spinal tuberculosis, natural history of disease, classifications and principles of management with historical perspective.

Authors:  Kush Kumar
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-07-19

Review 4.  History of Spinal Fusion: Where We Came from and Where We Are Going.

Authors:  Sohrab Virk; Sheeraz Qureshi; Harvinder Sandhu
Journal:  HSS J       Date:  2020-02-25

Review 5.  Atypical imaging features of tuberculous spondylitis: case report with literature review.

Authors:  Rita Momjian; Mina George
Journal:  J Radiol Case Rep       Date:  2014-11-30

6.  Treatment of pediatric spinal tuberculosis abscess with percutaneous drainage and low-dose local antituberculous therapy: a preliminary report.

Authors:  Xin Hua Yin; Hong Qi Zhang; Xiong Ke Hu; Jin Song Li; Yong Chen; Ke Feng Zeng
Journal:  Childs Nerv Syst       Date:  2015-04-12       Impact factor: 1.475

7.  Tuberculosis the great masquerader.

Authors:  Elizabeth Wenqian Wang; Christine N Okwesili; James B Doub
Journal:  IDCases       Date:  2022-06-18

Review 8.  Imaging update in spinal tuberculosis.

Authors:  Vijay Kubihal; Raju Sharma; R G Krishna Kumar; S H Chandrashekhara; Rakesh Garg
Journal:  J Clin Orthop Trauma       Date:  2021-12-09

9.  Debridement, internal fixation, and reconstruction using titanium mesh for the surgical treatment of thoracic and lumbar spinal tuberculosis via a posterior-only approach: a 4-year follow-up of 28 patients.

Authors:  Hongqi Zhang; Kefeng Zeng; Xinghua Yin; Jia Huang; Mingxing Tang; Chaofeng Guo
Journal:  J Orthop Surg Res       Date:  2015-09-22       Impact factor: 2.359

10.  The outcomes of chemotherapy only treatment on mild spinal tuberculosis.

Authors:  Zehua Zhang; Fei Luo; Qiang Zhou; Fei Dai; Dong Sun; Jianzhong Xu
Journal:  J Orthop Surg Res       Date:  2016-05-14       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.